ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Ferrata Storti Foundation
2019-02-01
|
| Rangatū: | Haematologica |
| Urunga tuihono: | https://haematologica.org/article/view/8789 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|